Roche and early users presented early data for the Axelios 1 sequencing‑by‑expansion (SBX) nanopore platform at AMP, positioning the instrument for rapid cancer genomics and ctDNA analysis. Hartwig Medical Foundation results showed high concordance with Illumina NovaSeq for tumor‑normal whole‑genome datasets, and Roche demonstrated fast ctDNA variant detection and a path to concurrent variant plus methylation calls. Roche emphasized automated library prep, high throughput batching and speed as differentiators. The company also previewed XOOS analysis tools to support downstream mutation calling in clinical research applications, but regulatory validation and broader clinical utility studies remain required before diagnostic deployment.